UTMD vs. CERS, ANIK, OSUR, CTSO, CODX, ATRI, ANGO, RCEL, TLSI, and INO
Should you be buying Utah Medical Products stock or one of its competitors? The main competitors of Utah Medical Products include Cerus (CERS), Anika Therapeutics (ANIK), OraSure Technologies (OSUR), Cytosorbents (CTSO), Co-Diagnostics (CODX), Atrion (ATRI), AngioDynamics (ANGO), AVITA Medical (RCEL), TriSalus Life Sciences (TLSI), and Inovio Pharmaceuticals (INO). These companies are all part of the "surgical & medical instruments" industry.
Cerus (NASDAQ:CERS) and Utah Medical Products (NASDAQ:UTMD) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, community ranking, media sentiment and valuation.
Utah Medical Products has a net margin of 33.40% compared to Utah Medical Products' net margin of -19.27%. Cerus' return on equity of 13.06% beat Utah Medical Products' return on equity.
Cerus currently has a consensus target price of $3.83, suggesting a potential upside of 94.59%. Given Utah Medical Products' higher probable upside, equities analysts plainly believe Cerus is more favorable than Utah Medical Products.
Cerus has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500. Comparatively, Utah Medical Products has a beta of 0.15, suggesting that its stock price is 85% less volatile than the S&P 500.
In the previous week, Cerus had 2 more articles in the media than Utah Medical Products. MarketBeat recorded 2 mentions for Cerus and 0 mentions for Utah Medical Products. Utah Medical Products' average media sentiment score of 0.80 beat Cerus' score of 0.67 indicating that Cerus is being referred to more favorably in the media.
Cerus received 416 more outperform votes than Utah Medical Products when rated by MarketBeat users. Likewise, 72.26% of users gave Cerus an outperform vote while only 61.29% of users gave Utah Medical Products an outperform vote.
78.4% of Cerus shares are held by institutional investors. Comparatively, 69.6% of Utah Medical Products shares are held by institutional investors. 7.1% of Cerus shares are held by company insiders. Comparatively, 6.6% of Utah Medical Products shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Utah Medical Products has lower revenue, but higher earnings than Cerus. Cerus is trading at a lower price-to-earnings ratio than Utah Medical Products, indicating that it is currently the more affordable of the two stocks.
Summary
Cerus beats Utah Medical Products on 10 of the 17 factors compared between the two stocks.
Get Utah Medical Products News Delivered to You Automatically
Sign up to receive the latest news and ratings for UTMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding UTMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Utah Medical Products Competitors List
Related Companies and Tools
